Market closed
Tyra Biosciences/TYRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tyra Biosciences
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Ticker
TYRA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
49
Website
Tyra Biosciences Metrics
BasicAdvanced
$1.5B
Market cap
-
P/E ratio
-$1.66
EPS
1.02
Beta
-
Dividend rate
Price and volume
Market cap
$1.5B
Beta
1.02
52-week high
$27.66
52-week low
$10.38
Average daily volume
218K
Financial strength
Current ratio
36.464
Quick ratio
36.187
Long term debt to equity
1.6
Total debt to equity
1.702
Management effectiveness
Return on assets (TTM)
-18.57%
Return on equity (TTM)
-26.50%
Valuation
Price to book
4.01
Price to tangible book (TTM)
4.01
Price to free cash flow (TTM)
-21.899
Growth
Earnings per share change (TTM)
38.54%
3-year earnings per share growth (CAGR)
-41.49%
What the Analysts think about Tyra Biosciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Tyra Biosciences stock.
Tyra Biosciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Tyra Biosciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Tyra Biosciences News
AllArticlesVideos
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?
Benzinga·1 day ago
Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point
Seeking Alpha·5 days ago
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
Benzinga·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tyra Biosciences stock?
Tyra Biosciences (TYRA) has a market cap of $1.5B as of October 26, 2024.
What is the P/E ratio for Tyra Biosciences stock?
The price to earnings (P/E) ratio for Tyra Biosciences (TYRA) stock is 0 as of October 26, 2024.
Does Tyra Biosciences stock pay dividends?
No, Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Tyra Biosciences dividend payment date?
Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Tyra Biosciences?
Tyra Biosciences (TYRA) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.